K
28.38
-0.68 (-2.34%)
| Previous Close | 29.06 |
| Open | 28.91 |
| Volume | 569,965 |
| Avg. Volume (3M) | 667,856 |
| Market Cap | 2,070,916,864 |
| Price / Sales | 4.40 |
| Price / Book | 4.64 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Kiniksa Pharmaceuticals, Ltd. | Bearish | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 3.0 |
| Insider Activity | -2.5 |
| Price Volatility | -1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.40 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.83% |
| % Held by Institutions | 96.14% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (Jefferies, 58.56%) | Buy |
| Median | 39.50 (39.18%) | |
| Low | 34.00 (Wedbush, 19.80%) | Buy |
| Average | 39.50 (39.18%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 23.21 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 29 Apr 2025 | 45.00 (58.56%) | Buy | 25.88 |
| Wedbush | 16 Apr 2025 | 34.00 (19.80%) | Buy | 20.54 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| TESSARI EBEN | - | 28.41 | -17,300 | -491,493 |
| Aggregate Net Quantity | -17,300 | |||
| Aggregate Net Value ($) | -491,493 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 28.41 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TESSARI EBEN | Officer | 16 Jun 2025 | Automatic sell (-) | 17,300 | 28.41 | 491,493 |
| TESSARI EBEN | Officer | 16 Jun 2025 | Option execute | 6,500 | - | - |
| Date | Type | Details |
|---|---|---|
| 05 Jun 2025 | Announcement | Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis |
| 29 May 2025 | Announcement | Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences |
| 30 Apr 2025 | Announcement | Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis |
| 29 Apr 2025 | Announcement | Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution |
| 24 Apr 2025 | Announcement | Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |